EGFR and non-small cell lung carcinoma: To our knowledge, this is the first study specifically focused on comparing the efficacy and toxicity of the third‐gen EGFR TKIs (osimertinib, aumolertinib, furmonertinib, befotertinib, lazertinib, and rilertinib) in treatment‐naive patients with advanced EGFR‐mutated NSCLC.